Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-18
2007-12-18
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000
Reexamination Certificate
active
11395824
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5571813 (1996-11-01), Ruhter et al.
patent: 5602137 (1997-02-01), Ruhter et al.
patent: 5602138 (1997-02-01), Miller
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 6723136 (2004-04-01), Pruche
patent: 2002/0124330 (2002-09-01), Pruche
patent: 2002/0178512 (2002-12-01), Pastove
patent: 102 23 917 (2003-12-01), None
patent: 0 714 898 (1996-06-01), None
patent: 0 628 559 (2002-04-01), None
patent: 1 210 931 (2002-06-01), None
patent: 1 334 973 (2003-08-01), None
patent: 40002672 (1965-02-01), None
patent: 41014423 (1966-08-01), None
patent: 41015583 (1966-09-01), None
patent: 41016288 (1966-09-01), None
patent: 61057587 (1986-03-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 01/62220 (2001-08-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 03/091256 (2003-11-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Senderowicz et al., “Phase 1 Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns”,Journal of Clinical Oncology, 18(9): 2986-2999 (Sep. 1998).
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem, 243:527-536 (1997).
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research, 57: 3375-3380 (Aug. 15, 1997).
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-α]pyrimidine Derivatives”,Chem. Pharm. Bull., 47(7): 828-838 (1999).
Yasuo, Makisumi, “Studies on the Azaindolizine Compounds. XI, Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines”,Chem. Pharm. Bull(1982), 10:620-628.
Patent Abstracts of Japan vol. 2000, No. 1, Jan. 31, 2000 & JP11 292879 A, Otsuka Pharmaceut Factory Inc., Oct. 28, 1999 abstract.
Gray, Nathanael et al., “ATP-site Directed Inhibitors of Cyclin-dependent Kinases”, 6(9): 859-875 (1999).
Translation of WO 03/91256,A Rising Sun Communications Ltd. Translation Product, (1-62), 4118/2003.
West, Anthony R., “Solid State Chemistry and its Applications”,Wiley, New York, 358 and 365 (1988).
Fischer, Peter M. et al., “Recent progress in the discovery and development of cyclin-dependent kinase inhibitors”,Expert Opinion on Investigational Drugs, 14(4): 457-477 (Apr. 2005).
Fischer, Peter M. et al., “CDK Inhibitors in clinical development for the treatment of cancer”,Expert Opinion on Investigational Drugs, 12(6): 955-970 (Jun. 2003).
Bennett, J. Claude, et al. “Cecil Textbook of Medicine”, 20thedition, 1: 1004-1010 (1996).
Mass, Robert D., “The Her Receptor Family: A Rich Target for Therapeutic Development”,Int. J. Radiation Oncology Bio Phys., 58(3): 932-940 (2004).
Fabbro, Doriano, et al., “Protein kinases as targets for anticancer agents: from inhibitions to useful drugs”,Pharmacology&Therapeutics93: 79-98 (2002).
PCT International Search Report dated Dec. 29, 2003 for corresponding PCT Application No. PCT/US03/27502.
Chemical Abstract No. 63:10201 English Translation of JP 40002672.
Chemical Abstract No. 65:108095 English Translation of JP 41014423.
Chemical Abstract No. 66:10957 English Translation of JP 41015583.
Chemical Abstract No. 66:10952 English Translation of JP 41016288.
Chemical Abstract No. 105:226617 English Translation of JP 61057587.
Robins et al., “Purine Analog Inhibitors of Xanthine Oxidase—Structure Activity Relationships and Proposed Binding of the Molybdenum Cofactor”,J. Heterocyclic Chem., 22:601-634 (1985).
Vesely et al., “Inhibitor of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem, 224: 771-786 (1994).
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”, Journal of Medicinal Chemistry, 45, 2905-3927, 2002.
Mettey et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects”,J. Med. Chem., 46(2): 222-236 (2003).
Novinson et al., “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-α]pyrimidines”, J.Med. Chem., 20(2): 296-299 (1977).
Dillard Lawrence W.
Doll Ronald J.
Dwyer Michael P.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Balasubramanian Venkataraman
Farquharson-Torres Serena I.
Kalyanaraman Palaiyur S.
Schering Corporation
LandOfFree
Pyrazolopyrimidines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrimidines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3894218